Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James Hamilton

Showing results (101-110 of 122) with videos related to

Pageof 13
Sort By:
Otolaryngology--Head and Neck Surgery : Official Journal of American Academy of Otolaryngology-Head and Neck Surgery|June 24, 2020
Narrowband Imaging for p16+ Unknown Primary Squamous Cell Carcinoma Prior to Transoral Robotic SurgeryKareem Al-Mulki, James Hamilton, Azeem S Kaka, et al.
Nature Medicine|April 7, 2026
Zodasiran for cholesterol and triglyceride lowering in patients with hyperlipidemia: final report of phase 1 basket trialGerald F Watts, Russell Scott, David Sullivan, et al.
Antiviral Therapy|June 13, 2022
JNJ-73763989 pharmacokinetics and safety: Liver-targeted siRNAs against hepatitis B virus, in Japanese and non-Japanese healthy adults, and combined with JNJ-56136379 and a nucleos(t)ide analogue in patients with chronic hepatitis BEd Gane, Man-Fung Yuen, Thomas N Kakuda, et al.
Circulation|April 7, 2004
In vivo molecular imaging of acute and subacute thrombosis using a fibrin-binding magnetic resonance imaging contrast agentRené M Botnar, Alexandra S Perez, Sonia Witte, et al.
The Lancet. Diabetes & Endocrinology|December 21, 2025
Zodasiran, an RNAi therapeutic targeting ANGPTL3, for treating patients with homozygous familial hypercholesterolaemia (GATEWAY): an open-label, randomised, phase 2 trialFrederick J Raal, Jean Bergeron, Daniel Gaudet, et al.
Nature Medicine|August 25, 2023
RNA interference targeting ANGPTL3 for triglyceride and cholesterol lowering: phase 1 basket trial cohortsGerald F Watts, Christian Schwabe, Russell Scott, et al.
NEJM Evidence|February 6, 2024
RNA Interference Therapy Targeting Apolipoprotein C-III in HypertriglyceridemiaDaniel Gaudet, Peter Clifton, David Sullivan, et al.
Science Translational Medicine|September 29, 2017
RNAi-based treatment of chronically infected patients and chimpanzees reveals that integrated hepatitis B virus DNA is a source of HBsAgChristine I Wooddell, Man-Fung Yuen, Henry Lik-Yuen Chan, et al.
JCI Insight|May 8, 2020
Development of an RNAi therapeutic for alpha-1-antitrypsin liver diseaseChristine I Wooddell, Keith Blomenkamp, Ryan M Peterson, et al.
Hepatology (Baltimore, Md.)|October 27, 2019
RNA Interference Therapy With ARC-520 Results in Prolonged Hepatitis B Surface Antigen Response in Patients With Chronic Hepatitis B InfectionMan-Fung Yuen, Ingolf Schiefke, Jung-Hwan Yoon, et al.
Pageof 13

Showing results (101-110 of 122) with videos related to

Sort By:
Pageof 13
Otolaryngology--Head and Neck Surgery : Official Journal of American Academy of Otolaryngology-Head and Neck Surgery|June 24, 2020
Narrowband Imaging for p16+ Unknown Primary Squamous Cell Carcinoma Prior to Transoral Robotic SurgeryKareem Al-Mulki, James Hamilton, Azeem S Kaka, et al.
Nature Medicine|April 7, 2026
Zodasiran for cholesterol and triglyceride lowering in patients with hyperlipidemia: final report of phase 1 basket trialGerald F Watts, Russell Scott, David Sullivan, et al.
Antiviral Therapy|June 13, 2022
JNJ-73763989 pharmacokinetics and safety: Liver-targeted siRNAs against hepatitis B virus, in Japanese and non-Japanese healthy adults, and combined with JNJ-56136379 and a nucleos(t)ide analogue in patients with chronic hepatitis BEd Gane, Man-Fung Yuen, Thomas N Kakuda, et al.
Circulation|April 7, 2004
In vivo molecular imaging of acute and subacute thrombosis using a fibrin-binding magnetic resonance imaging contrast agentRené M Botnar, Alexandra S Perez, Sonia Witte, et al.
The Lancet. Diabetes & Endocrinology|December 21, 2025
Zodasiran, an RNAi therapeutic targeting ANGPTL3, for treating patients with homozygous familial hypercholesterolaemia (GATEWAY): an open-label, randomised, phase 2 trialFrederick J Raal, Jean Bergeron, Daniel Gaudet, et al.
Nature Medicine|August 25, 2023
RNA interference targeting ANGPTL3 for triglyceride and cholesterol lowering: phase 1 basket trial cohortsGerald F Watts, Christian Schwabe, Russell Scott, et al.
NEJM Evidence|February 6, 2024
RNA Interference Therapy Targeting Apolipoprotein C-III in HypertriglyceridemiaDaniel Gaudet, Peter Clifton, David Sullivan, et al.
Science Translational Medicine|September 29, 2017
RNAi-based treatment of chronically infected patients and chimpanzees reveals that integrated hepatitis B virus DNA is a source of HBsAgChristine I Wooddell, Man-Fung Yuen, Henry Lik-Yuen Chan, et al.
JCI Insight|May 8, 2020
Development of an RNAi therapeutic for alpha-1-antitrypsin liver diseaseChristine I Wooddell, Keith Blomenkamp, Ryan M Peterson, et al.
Hepatology (Baltimore, Md.)|October 27, 2019
RNA Interference Therapy With ARC-520 Results in Prolonged Hepatitis B Surface Antigen Response in Patients With Chronic Hepatitis B InfectionMan-Fung Yuen, Ingolf Schiefke, Jung-Hwan Yoon, et al.
Pageof 13